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Abstract
Background: Cognate immunity against neoplastic cells depends on a balance between effector T cells
and regulatory T (Treg) cells. Treg cells prevent immune attack against normal and neoplastic cells by
directly suppressing the activation of effector CD4+ and CD8+ T cells. We postulated that a recombinant
interleukin 2/diphtheria toxin conjugate (DAB/IL2; Denileukin Diftitox; Ontak) may serve as a useful
strategy to deplete Treg cells and break tolerance against neoplastic tumors in humans.
Methods: We administered DAB/IL2 (12 μg/kg; four daily doses; 21 day cycles) to 16 patients with
metastatic melanoma and measured the effects on the peripheral blood concentration of several T cell
subsets and on tumor burden.
Results: We found that DAB/IL2 caused a transient depletion of Treg cells as well as total CD4+ and CD8+
T cells (< 21 days). T cell repopulation coincided with the de novo appearance of melanoma antigen-specific
CD8+ T cells in several patients as determined by flow cytometry using tetrameric MART-1, tyrosinase
and gp100 peptide/MHC conjugates. Sixteen patients received at least one cycle of DAB/IL2 and five of
these patients experienced regressions of melanoma metastases as measured by CT and/or PET imaging.
One patient experienced a near complete response with the regression of several hepatic and pulmonary
metastases coupled to the de novo appearance of MART-1-specific CD8+ T cells. A single metastatic tumor
remained in this patient and, after surgical resection, immunohistochemical analysis revealed MART1+
melanoma cells surrounded by CD8+ T cells.
Conclusion: Taken together, these data indicate that transient depletion of T cells in cancer patients may
disrupt the homeostatic control of cognate immunity and allow for the expansion of effector T cells with
specificity against neoplastic cells. Several T cell depleting agents are clinically available and this study
provides strong rationale for an examination of their efficacy in cancer patients.
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Background
Of the common adult-onset cancers, melanoma is widely
held to be the most amenable to immunotherapeutic
intervention. This perception is based on the following:
(i) several melanoma-specific antigens have been identi-
fied; (ii) melanoma antigen-specific CD4+ and CD8+ T
lymphocytes are increased in melanoma patients and
have anti-tumor activity; (iii) immune-enhancing agents
can cure mice of established melanomas; and (iv) sponta-
neous melanoma regressions in humans with the simulta-
neous onset of vitiligo have been reported [1,2].
Additionally, the immune-enhancing agent, interferon-α,
increases survival in melanoma patients with intermedi-
ate or high risk of recurrence, and high-dose interleukin 2
(IL-2), a potent stimulator of T cell proliferation, causes
durable remissions in a small subset of patients with met-
astatic melanoma [3-5].
Cognate immune reactions against tumor cells depend on
a balance between activated tumor antigen specific CD4+
and CD8+ T cells and suppressive regulatory T cells [6].
CD4+CD25HI regulatory T (Treg) cells directly suppress
the activation of anti-tumor effector T cells in a contact-
dependent manner [7,8]. Depletion of these immunosup-
pressive Treg cells using anti-CD25 monoclonal antibod-
ies enables a CD8+ and CD4+ T cell dependent immune
rejection against the progression of melanoma in mice
[7,9,10]. This anti-tumor activity is not exclusive to
melanoma since it has been observed against several
transplantable mouse tumor cell lines in multiple dispa-
rate mouse strains [11-13]. Furthermore, down-regulation
of Treg cell function can be accomplished with certain
stimulatory antibodies (e.g. anti-GITR [DTA-1]) and this
treatment confers concomitant tumor immunity against
remote tumors even in poorly immunogenic mouse
melanomas [10]. Treg cells thus may function to tolerize
or deactivate cognate effector CD4+ and CD8+ T cells to
neoplastic cells that express tumorigenic antigens. Accord-
ingly, the selective depletion of these cells may have clin-
ical utility for the induction of anti-tumor immunity.
A multitude of successful treatment strategies in tumor-
bearing mice have failed when examined in human clini-
cal trials, and correlative data that provide additional
rationale for clinical trials in humans is essential. Viguier
et al. reported the results of an immunohistochemical
examination for the presence of CD4+CD25HI Treg cells in
lymph nodes with and without metastasic melanoma
seeds extracted from twelve patients with metastatic
melanoma (Stage IIIb/IIIc) [14]. They observed that the
frequency of Treg cells in melanoma-positive lymph
nodes was 11.06% whereas the frequency was only 6.2%
in melanoma-free lymph nodes [14]. The over-representa-
tion of Treg cells in metastatic lymph nodes suggests that
these cells may be recruited and/or expanded at the tumor
site. Treg cells isolated from the metastatic lymph nodes
were found to inhibit CD4+ and CD8+ T cell proliferation
in vitro via a contact-dependent mechanism and thus
appear to function similarly to the well characterized
mouse Treg cells. Taken together, these data provide cor-
relative evidence that CD25+ Treg cells may be functioning
to suppress anti-tumor immunity in melanoma patients.
Denileukin diftitox (DAB/IL2; Ontak) is a recombinant
DNA-derived cytotoxic protein composed of diphtheria
toxin fragments A and B and the full-length IL-2 molecule.
DAB/IL2 binds to CD25 (the α chain of the IL-2 receptor)
and, following internalization, inhibits protein synthesis,
causing cell death within hours [15]. DAB/IL2 is FDA-
approved for the treatment of patients with persistent or
recurrent cutaneous T cell lymphoma (CTCL) whose
malignant cells express CD25. CTCL malignant prolifera-
tion is driven by interaction with cutaneous dendritic cells
(termed Langerhans cells), and this epidermal association
of CTCL cells with Langerhans cells is a hallmark of the
malignancy [16]. In recent studies, purified human CTCL
cells were incubated with dendritic cells and found to
adopt a Treg phenotype, including: (i) expression of the
negative T cell regulator, cytotoxic T lymphocyte antigen-
4 (CTLA-4); (ii) expression of the Treg specific transcrip-
tion factor, Foxp3; and (iii) the ability to suppress CD4+ T
cell activation [16]. Based on these findings, CTCL has
been postulated to be a malignant proliferation of Treg
cells and, coupled to the observation that Treg cells
express high surface CD25, these data provide rationale
for the testing of DAB/IL2 as a selective Treg-depleting
agent.
In the current study, we have found that DAB/IL2 admin-
istration to stage IV melanoma patients depletes periph-
eral blood Treg cells and causes the regression of
metastatic tumors in a subset of patients. We also
observed a significant depletion of the total T cell popula-
tion including CD4+CD25- T cells that was reversed within
21 days of DAB/IL2 administration. We speculate that
transient depletion of T cells in cancer patients may dis-
rupt the homeostatic control of cognate immunity and
allow an expansion of CD8+ T cells with increased specif-
icity for the peptide/MHC complexes expressed by neo-
plastic cells.
Methods
Patient enrollment
This clinical trial was approved by the University of Louis-
ville Human Studies Committee. Only patients with dis-
tant metastases from cutaneous or mucosal melanoma or
melanoma of unknown primary were eligible for inclu-
sion. All patients fulfilled the following criteria: (i) pri-
mary tumor must have been documented by
histopathologic analysis; (ii) metastatic disease must haveJournal of Translational Medicine 2008, 6:12 http://www.translational-medicine.com/content/6/1/12
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been documented by radiologic examinations (CT scan or
PET scan) with bidimensional measurements; and (iii)
disease recurrences occurring greater than five years after
the original diagnosis must have been biopsy proven.
DAB/IL2 administration
All patients were subjected to fusion PET/CT or CT imag-
ing within one month prior to receiving the first dose of
DAB/IL2 and within one month after receiving the last
dose of DAB/IL2. DAB/IL2 was administered as follows:
12 μg/kg, IV over 30 minutes every 24 hours for 4 doses
(cycles repeated every 21 days). All patients had renal
function tests, blood counts, and a thorough physical
examination, including neurological examination, prior
to each cycle of DAB/IL2. The endpoint definitions were
as follows:
Clinical complete response (CR)
Disappearance of all evidence of tumor. The patient must
be free of all symptoms of cancer.
Partial response (PR)
30% or greater decrease in the sum of the longest diameter
of target lesions, taking as reference the baseline sum
longest diameter.
Progressive disease (PD)
At least 20% increase in the sum of the longest diameter
of target lesions, taking as reference the baseline sum
longest diameter, or the appearance of new lesions and/or
unequivocal progression of existing non-target lesion.
Stable disease (SD)
Neither sufficient shrinkage to qualify for partial response
nor sufficient increase to qualify for progressive disease,
taking as reference the smallest sum longest diameter
since the treatment started.
Monocyte, granulocyte, lymphocyte and T cell subset 
quantification
Whole blood (50 ml) was collected in heparinized tubes
and the absolute lymphocyte, granulocyte and monocyte
peripheral blood concentrations were determined with a
Sysmex XE-2100 Automated Hematology Analyzer.
PBMCs were then isolated by centrifugation through
Accuspin System Histopaque 1077 and washed twice with
PBS.
In order to determine the percentage of CD4+, CD4+/
CD25-, CD4+/CD25+, CD4+/CD25HI, CD4+/CD25HI/
Foxp3-, and CD4+/CD25HI/Foxp3+ T cells within the lym-
phocyte gate (based on forward/side scatter profile), we
incubated the total PBMCs with PE-anti-Foxp3, FITC-anti-
CD4, and APC-anti-CD25 (eBioscience). 100 μl of PBMCs
(1 × 106) were added to 20 μl of an anti-CD4/and-CD25
cocktail (1 μg anti-CD4 and 0.125 μg anti-CD25; eBio-
science) and incubated for 30 minutes in the dark at 4°C
and then washed in cold PBS. After decanting, the cell pel-
let was resuspended in residual buffer and 1 ml of freshly
prepared eBioscience Fixation/Permeabilization Buffer
was added to each sample and incubated at 4°C for 60
minutes in the dark. 2 ml of Permeabilization Buffer was
used for washing followed by centrifugation and decant-
ing of supernatant. 20 μl anti-human Foxp3 (PCH101)
antibody or 20 μl rat IgG2b isotype control was added to
resuspended cells and incubated at 4°C for 30 minutes in
the dark. Cells were washed twice in 2 ml Permeabiliza-
tion Buffer. Small lymphocytes were gated according to
forward/side-scatter profiles and data was collected on a
FACSCalibur flow cytometer within 1 hour after staining,
and then analyzed with Cell Quest software (Becton Dick-
inson).
In order to detect the percentage of total CD8+ cells, and
MART1-, gp100- and tyrosinase-specific CD8+ T cells
within the lymphocyte gate (based on forward/side scatter
profile), 106 PBMCs in 200 μl of flow cytometry staining
buffer were incubated at 25°C for 30 minutes in the dark
with 1.0 μg of APC-labeled tetramer (MART-1, gp100 or
tyrosinase; Immunomics, Beckman Coulter) and 0.25 μg
CD8-PE monoclonal antibody (R&D Systems). Small
lymphocytes were gated according to forward/side-scatter
profiles and then the percentage of tetramer+CD8+ cells
was determined. Data was collected on a FACSCalibur
flow cytometer within 1 hour after staining, and analyzed
with Cell Quest software (Becton Dickinson).
The absolute concentrations of CD4+, CD4+/CD25-,
CD4+/CD25+, CD4+/CD25HI, CD4+/CD25HI/Foxp3-,
CD4+/CD25HI/Foxp3+, CD8+, CD8+/HLA-A2*0201-
MART1-binding, CD8+/HLA-A2*0201-gp100-binding
and CD8+/HLA-A2*0201-tyrosinase-binding cells were
quantified by determining the percentage of fluorescence-
positive cells within the forward/side scatter lymphocyte
gate (as detailed above), and then multiplying this per-
centage by the absolute lymphocyte concentration deter-
mined using the Sysmex XE-2100 Automated Hematology
Analyzer. The percent control of each sample was calcu-
lated by dividing the T cell subset absolute cell concentra-
tion on the indicated day of treatment with the cell
concentration on day 0 prior to DAB/IL2 administration
(× 100).
DAB/IL2 enzyme linked immunosorbent assay
Human plasma samples were tested for the presence of
IgG specific for DAB/IL2 by enzyme linked immunosorb-
ent assay (ELISA). The assay was carried out as follows: 96-
well microtest polystyrene assay plates (BD) were coated
(100 μL/well) with either Tris-NaCl pH 8.5 solution (30
mL 5 M NaCl + 50 mL 1 M Tris + 920 mL water) or DAB/Journal of Translational Medicine 2008, 6:12 http://www.translational-medicine.com/content/6/1/12
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IL2 (Ligand) diluted to 2 μg/mL in Tris-NaCl solution.
After incubating overnight at 37°C, the plates were
washed two times with Tris-NaCl solution. 300 μl PBS/
BSA (30 mL PBS + 300 mg BSA; Sigma) was then added to
each well and the plates were incubated for one hour at
37°C, followed by three washes with Tris-NaCl solution.
100 μl of test sera, diluted 1:500 in PBS/BSA solution, was
then added to each well. After incubating at 37°C for two
hours, the plates were washed three times with Tris-NaCl
+ 0.05% Tween (300 mL Tris-NaCl + 150 μl Tween). 100
μl of rabbit anti-human IgG HRP-conjugated antibody
(Pierce), diluted 1:50,000 in PBS/BSA, was then added to
each well and the plates incubated at 37°C for one hour,
followed by three washes with Tris-NaCl + 0.05% Tween
and two washes with DH2O. 100 μl of TMB substrate
(Pierce) was added to each well. After five minutes, the
reaction was stopped with 1N HCL (100 μl/well) and the
plates were read at 450 nm.
Immunohistochemistry
Five μm sections of formalin-fixed and paraffin-embed-
ded tumor tissue were mounted on charged glass slides
and dried at 58°C for 60 minutes. Slides were first depar-
affinized with xylene then incubated with a high temper-
ature epitope retrieval solution (20 min) and hydrogen
peroxide (H2O2) (for 10 min) to block endogenous per-
oxidases. The sections were incubated with primary anti-
body (anti-CD8, 1:50, Dako; anti-CD4, 1:50, Novocastra;
anti-HLA Class I [HLA-A, B, C], 1:500, clone EMR8-5,
MBL International) for 15 min, followed by a post-pri-
mary antibody and a polymer horse-radish-peroxidase
linked detection system (each for 8 min, Define, Leica
Microsystems). The sections were developed with 3,3'-
diaminobenzidine tetrahydrochloride (DAB) solution
(Invitrogen) for 10 min and nuclei counterstained with
hematoxylin (Dako) for 7 min. PBS washes were per-
formed between all steps. The slides were neutralized in
ammonia water, dehydrated in graded alcohols (100%,
95%, and 80% ethanol [vol/vol] in H2O), cleared in
xylene and coverslips attached with Permount (Fisher Sci-
entific).
For MART-1 staining, slides were deparaffinized (with
xylene), hydrated with distilled water and then placed in
citrate buffer (Dako) in a 72°C oven overnight for antigen
retrieval. Following treatment with H2O2, slides were
incubated in MART-1 primary antibody (1:40, Signet) for
25 min then in LSAB2 biotinylated link antibody (Dako)
for 20 min followed by a streptavidin-peroxidase reaction
using DAB as a chromogen. Slides were finally counter-
stained in hematoxylin and then neutralized, dehydrated
and coverslips attached as above. Double staining was
accomplished by first staining for CD8 (as above) using
DAB as the chromogen followed by washing and staining
for MART-1 using the alkaline phosphatase system (Leica)
omitting the deparaffinization and retrieval steps. Brown
staining from the DAB indicated CD8+ T cells and red
staining from the alkaline phosphatase indicated MART1+
cells. Both positive and negative controls were stained
with the specimens.
Cytotoxicity assay
CRL-11174 human melanoma cells (ATCC) were cultured
in 1 ml of Dulbecco's Modified Eagle Medium (DMEM)
(Hyclone, Logan, UT) supplemented with 10% fetal
bovine serum (FBS) (Hyclone, Logan, UT) and 50 μg/mL
gentamicin sulfate (Invitrogen, Carlsbad, CA) (2.5 × 105
cells/well, 6-well plate). DAB/IL2 (Ligand Pharmaceuti-
cals) or PBS was added to the culture (0.05–5 μg/ml) and,
after 48 hours, live and dead cells were enumerated by the
addition of trypan blue and direct visualization using
light microscopy.
Results
DAB/IL2 transiently depletes CD4+, CD8+ and CD4+/
CD25+/Foxp3+ T cells
We administered DAB/IL2 (12 μg/kg daily × four days) to
stage IV melanoma patients and measured the peripheral
blood concentration of lymphocytes, granulocytes and
monocytes on days 0, 1, 2, 3, 4, 7 and 21 using an auto-
mated hematology analyzer (Figure 1A; n = 10). We
observed a reduction in the absolute lymphocyte concen-
tration and an increase in granulocytes and monocytes
within 48 hours of DAB/IL2 administration. Next, the
absolute concentration of several T cell subsets was quan-
tified by multiplying the percentage of fluorescence-posi-
tive cells within the lymphocyte forward/side scatter gate
determined using flow cytometric analyses by the abso-
lute lymphocyte concentration determined using an auto-
mated hematology analyzer. We quantified the absolute
CD4+ and CD8+ T cell concentration in the peripheral
blood and found that both T cell subsets were reduced to
~ 50% of control within 24–48 hours of DAB/IL2 admin-
istration (Figure 1B; n = 10). We co-stained for CD4,
CD25 and Foxp3 expression and found that DAB/IL2
depleted the CD4+CD25HIFoxp3+ cell percentage in the
lymphocyte gate within 72 hours but that these
CD4+CD25HIFoxp3+  cells repopulated the peripheral
blood within 21 days (see Figure 2 for a representative
example; CD4+CD25HI cells [left panels] were gated and
examined for Foxp3 expression [right panels]). Co-stain-
ing for CD4, CD25 and Foxp3 allowed us to gate on sev-
eral distinct T cell populations and calculate peripheral
blood concentrations (based on the absolute lymphocyte
concentrations) in order to identify the T cell phenotypes
that are most sensitive to DAB/IL2 administration. We
were surprised that the peripheral blood CD4+CD25- T
cell concentration was depleted by DAB/IL2 albeit to a
lesser extent than CD4+CD25+ and CD4+CD25HI T cells
(Figure 3A; n = 10; p value < 0.05 for each comparison).Journal of Translational Medicine 2008, 6:12 http://www.translational-medicine.com/content/6/1/12
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Given that the targeting mechanism of DAB/IL2 is
through CD25, we can only speculate that the depletion
of CD4+CD25- cells is due to unidentified indirect conse-
quences of CD4+CD25+ T cell depletion. Interestingly,
Foxp3 expression did not significantly alter sensitivity to
DAB/IL2 since the depletion of CD4+CD25HIFoxp3+ and
CD4+CD25HIFoxp3- was not statistically different (Figure
3B; p value = 0.424).
In four patients that received four 3-week cycles (P3, P7,
P9 and P16), we found that the T cell depletion and
inverse increase in peripheral blood monocytes was
blunted in cycles 2–4 of DAB/IL2 (Figures 4A, 4C, 4E, and
4G; arrows indicate cycles) and that this effect was coinci-
dent with the appearance of anti-DAB/IL2-specific IgG as
measured by ELISA (Figures 4B, 4D, 4F, and 4H). Addi-
tionally, we found that the CD4+CD25HIFoxp3+ T cells
were depleted to a greater extent relative to CD8+ T cells
after 4 cycles of DAB/IL2 administration (day 70;
CD4+CD25HIFoxp3+ T cells = 37 ± 16% of control; CD8+
T cells, 128 ± 48% of control; n = 4; p value = 0.031; Fig-
ures 4A, 4C, 4E, and 4G). Although the total CD4+ T cell
recovery after 4 cycles of DAB/IL2 appeared not to be as
robust as that observed by the CD8+ T cells, we observed
no statistically significant difference in these T cell subsets
(CD4+ T cells, 73 ± 25% of control; CD8+ T cells, 128 ±
48% of control; n = 4; p value = 0.086).
T cell repopulation after DAB/IL2 monotherapy is 
associated with the de novo appearance of melanoma 
antigen-specific CD8+ T cells
Seven patients expressed the HLA-A2*0201 class I MHC
necessary for tetramer-based measurement of CD8+ T lym-
phocytes specific for the melanoma antigens, MART1,
tyrosinase and gp100. We did not detect CD8+ T cells spe-
cific for these three melanoma peptide/MHC conjugates
prior to DAB/IL2 administration in any of the examined
seven patients (data not shown). However, we did observe
the de novo appearance of MART1-specific CD8+ T cells in
four HLA-A2*0201+ patients after one cycle of DAB/IL2 as
well as CD8+ T cells specific for gp100 and tyrosinase in 2
and 3 patients, respectively (Figures 5 and 6). Interest-
ingly, DAB/IL2 transiently decreased the newly detectable
MART1-specific CD8+ T cells in three patients at the initi-
ation of cycles 2 and 3 (see Figures 6B–D). These data sup-
port the hypothesis that transient depletion of T cells in
melanoma patients may disrupt the homeostatic control
of cognate immunity and allow for the expansion of effec-
tor T cells with specificity against melanoma cells.
DAB/IL2 decreases tumor burden in stage IV melanoma 
patients
Sixteen heavily pre-treated stage IV melanoma patients
were administered 1–4 cycles of DAB/IL2 (12 μg/kg daily
× four days every 3 weeks). Positron emission tomogra-
phy and/or computed tomography were used to evaluate
the patients' baseline tumor burden and potential
responses three months from initiation of therapy. Table
1 details the characteristics of the patients and the
DAB/IL2 transiently depletes CD4+ and CD8+ T cells in  melanoma patients Figure 1
DAB/IL2 transiently depletes CD4+ and CD8+ T cells 
in melanoma patients. 10 patients with stage IV meta-
static melanoma were administered DAB/IL2 (intravenous; 
12 μg/kg) daily × 4 days (arrows indicate each administra-
tion). Whole blood was collected on the indicated days and 
analyzed for absolute lymphocyte (black), granulocyte (red) 
and monocyte (green) concentration with an automated 
hematology analyzer (A) and absolute CD4+ and CD8+ T cell 
concentration by flow cytometry (B). The peripheral blood 
concentrations of CD4+ and CD8+ T cells were quantified by 
multiplying the percentage of anti-CD4 or anti-CD8 fluores-
cence-positive cells within the lymphocyte forward/side scat-
ter gate by the absolute lymphocyte concentration 
determined using an automated hematology analyzer. Per-
cent control of each sample was calculated by dividing the 
absolute cell concentration on the indicated day of treatment 
with the absolute cell concentration on day 0 prior to DAB/
IL2 administration (× 100). Data are represented as averages 
± standard error of the mean (n = 10 patients).
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DAB/IL2 transiently depletes CD4+/CD25HI/Foxp3+ T cells Figure 2
DAB/IL2 transiently depletes CD4+/CD25HI/Foxp3+ T cells. Whole blood was collected from patient P9 during cycle 
one of DAB/IL2 administration just prior to the first (day 0) and last dose (day 3) and then 7 and 21 days after initiation of 
DAB/IL2 therapy. The peripheral blood mononuclear cells were isolated from the whole blood by Ficoll gradient centrifugation 
and stained with fluorescent conjugates of monoclonal antibodies specific for CD4, CD25 and Foxp3. In order to quantify the 
percentage of CD4+/CD25HI/Foxp3+ T cells within the total lymphocyte forward/side scatter gate, the CD4+/CD25HI cells 
(right panels) were gated and analyzed for Foxp3 expression (left panels).
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observed responses as per RECIST criteria. We observed
reductions in tumor burden in five patients and stabiliza-
tion of disease in one patient. Patient P3 had developed
rapidly progressing subcutaneous, hepatic and mesenteric
metastases but after 4 cycles of DAB/IL2, experienced
regression of 7 tumors as measured by PET/CT imaging
(Figure 7A). Interestingly, the two largest metastases at
baseline grew during treatment. Patient P5 experienced
regression of two large melanoma metastases, a right hilar
and a right colonic mass (Figure 7B). Patient P8 had sev-
eral palpable subcutaneous and intramuscular metastases
in her right lower extremity decrease in volume by physi-
cal exam after the first cycle of DAB/IL2. She completed
four cycles of DAB/IL2, and CT imaging confirmed a
decrease in the size of all metastases (Figure 8A). Patient
P9 developed swelling in his right inguinal basin and CT
imaging confirmed the development of a large right
inguinal mass over a 3 month interval. He experienced
decreased swelling after two cycles which was confirmed
by CT imaging after a total of four cycles of DAB/IL2 (Fig-
ure 8B). This mass did not change in size for the next 3
months and, after its surgical resection, the patient had no
further evidence of disease. The oldest patient enrolled
(79 years old; patient P12), developed two right hilar
metastases which became less prominent by PET imaging
after two cycles of DAB/IL2 (designated Stable Disease;
Figure 9).
Patient P14 developed widespread melanoma involving
the lungs, liver, subcutaneous compartment and adrenal
glands over a six month period (Figure 10). Clinically, he
was suffering from appetite and weight loss, fatigue, nau-
sea and shortness of breath. After four cycles of DAB/IL2,
PET/CT imaging revealed the complete regression of all
hepatic metastases and the majority of pulmonary metas-
tases (Figure 10). Follow-up PET/CT imaging three
months after completion of the fourth cycle of DAB/IL2
demonstrated resolution of the residual pulmonary
metastases but a persistently enlarged peri-aortic lymph
node. Surgical resection of this residual metastasis was
conducted and H&E staining revealed a mononuclear
infiltrate within a metastatic melanoma. Double immu-
nohistochemistry for the melanoma protein MART1 and
CD8 demonstrated that the melanoma cells (red staining)
were surrounded by infiltrating CD8+ T cells (brown
staining; Figure 11A) but not CD4+ T cells (data not
shown). These remaining melanoma cells were com-
pletely devoid of HLA-A, B or C expression as determined
using a monoclonal antibody specific for a non-polymor-
phic portion of these HLA molecules (Figure 11B; com-
pare positive controls, pancreas and unrelated melanoma,
to P14 residual metastasis). Coincident with this objective
response, the patient reported decreased pigmentation in
his hair and skin consistent with the development of vitil-
igo, an autoimmune disease against melanocytes (Figure
11C).
We were surprised by the high partial response rate in
these 16 patients and postulated that DAB/IL2 may
exhibit direct cytotoxic effects against human melanoma
cells. However, exposure of DAB/IL2 to proliferating
DAB/IL2 transiently depletes all analyzed CD4+ T cell subsets Figure 3
DAB/IL2 transiently depletes all analyzed CD4+ T cell 
subsets. Whole blood was collected from 10 patients 
throughout the first cycle of DAB/IL2 and analyzed for 
CD4+/CD25HI/Foxp3+ co-expression by flow cytometry as 
described in the Figure 2 legend and Methods section. The 
absolute concentration of CD4+/CD25- (black), CD4+/
CD25+ (red) and CD4+/CD25HI (green) T cells (A) and of 
CD4+/CD25HI/Foxp3- (black) and CD4+/CD25HI/Foxp3+ 
(red) T cells (B) were quantified by multiplying the percent-
age of anti-CD4, anti-CD25 and/or anti-Foxp3 fluorescence-
positive cells within the lymphocyte forward/side scatter gate 
by the absolute lymphocyte concentration determined using 
an automated hematology analyzer. The percent control of 
each sample was calculated by dividing the absolute cell con-
centration on the indicated day of treatment with the cell 
concentration on day 0 prior to DAB/IL2 administration (× 
100). Data are represented as averages ± standard error of 
the mean (n = 10 patients).
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Reduction in the T cell depleting activity of DAB/IL2 during cycles 2–4 is associated with the development of anti-DAB/IL2 IgG Figure 4
Reduction in the T cell depleting activity of DAB/IL2 during cycles 2–4 is associated with the development of 
anti-DAB/IL2 IgG. Whole blood was collected on the indicated days from patients P3 (A, B), P7 (C, D), P9 (E, F) and P16 
(G, H) throughout four cycles of DAB/IL2 administration (each cycle indicated by an arrow). CD4+ (black), CD8+ (red), CD4+/
CD25HI/Foxp3- (green) and CD4+/CD25HI/Foxp3+ (purple) T cells and monocytes (blue) were quantified as described in Fig-
ures 1 – 3 (A, C, E, H). Percent control of each sample was calculated by dividing the absolute cell concentration on the indi-
cated day of treatment with the cell concentration on day 0 prior to DAB/IL2 administration (× 100). Plasma was isolated on 
the indicated days and analyzed for the presence of anti-DAB/IL2 IgG by ELISA. For the ELISA, data are presented as averages 
± standard deviations (n = 5 per sample).
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Flow cytometric scatter plots demonstrating the de novo appearance of MART1-, gp100- and tyrosinase-specific CD8+ T cells  after one cycle of DAB/IL2 Figure 5
Flow cytometric scatter plots demonstrating the de novo appearance of MART1-, gp100- and tyrosinase-spe-
cific CD8+ T cells after one cycle of DAB/IL2. Whole blood was collected from patient P16 during cycle one of DAB/IL2 
administration just prior to (day 0) and 21 days after the first dose of DAB/IL2. The peripheral blood mononuclear cells were 
isolated from the whole blood by Ficoll gradient centrifugation and stained with a PE-labeled anti-CD8 monoclonal antibody 
and the indicated APC-labeled tetrameric HLA-A2*0201/peptide conjugates.
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human melanoma cells in vitro at a concentration 15-fold
higher than the obtainable peak plasma concentration of
DAB/IL2 in humans (0.3 μg/ml) had no effect on cell via-
bility or proliferation (0.05–5 μg/ml × 48 hours; vehicle
control, 7.12 ± 0.13 × 105 cells; + 5 μg/ml DAB/IL2, 7.35
± 0.37 × 105 cells; p value = 0.444).
Discussion
Melanoma incidence has risen by 25–31% over the last
decade and is now the 5th most common cancer in men
and the 6th  most common cancer in women [1,17].
Melanoma causes a disproportionate mortality in young
and middle-aged individuals and, as such, displays one of
the highest "loss of potential life" rates among the adult-
onset cancers (18.6 years per melanoma-related death)
[1]. In the United States, over 8000 adults die of
melanoma annually, and 84% of melanoma patients with
distant metastases succumb to their disease within 5 years
of diagnosis [1].
The treatment options for patients with metastatic
melanoma are limited to palliation or to aggressive ther-
apy with high dose IL-2 or biochemotherapy using cispla-
tin, vinblastine, dacarbazine, IL-2 and interferon α-2b.
The response rate to high dose IL-2 is low (16%) but dura-
ble cures have been observed in approximately 6–10% of
the patients that can tolerate the systemic toxicity (i.e.
hypotension, capillary leak syndrome, sepsis and renal
failure) [3,4]. Although biochemotherapy has been
reported to yield a 35–50% partial response rate and up to
a 20% complete response rate, median survival duration
is only 12.2 months [17,18]. Early published reports of
clinical trials of humanized anti-CTLA4 monoclonal anti-
bodies have indicated a 10–20% partial response rate in
melanoma patients [19]. In the current study, we
observed a 31% partial response rate after treatment with
DAB/IL2 (5/16 patients) which is clinically significant
given the low toxicity of this agent. Importantly, the
majority of patients who are treated with high dose IL-2,
biochemotherapy and/or anti-CTLA4 ultimately experi-
ence progression and few efficacious alternative treat-
ments are currently available.
We found that transient depletion of CD4+ and CD8+ T
cells in melanoma patients via targeting of IL-2 receptor-
expressing cells resulted in T cell repopulation in the
peripheral blood and the de novo appearance of CD8+ T
cells with specificity for melanoma antigens (in 4/7 HLA-
A2*0201 patients). We had anticipated that the detection
of peripheral blood MART1-, gp100- and tyrosinase-spe-
cific CD8+ T cells in these HLA-A2*0201+ patients might
correlate with tumor regressions. The three HLA-
A2*0201+ patients who did not develop any detectable
MART1-, gp100- and tyrosinase-specific CD8+ T cells also
did not experience regression of their melanoma metas-
De novo appearance of MART1-, gp100- and/or tyrosinase- specific CD8+ T cells in 4/7 HLA-A2*0201+ melanoma  patients after one cycle of DAB/IL2 Figure 6
De novo appearance of MART1-, gp100- and/or tyrosi-
nase-specific CD8+ T cells in 4/7 HLA-A2*0201+ 
melanoma patients after one cycle of DAB/IL2. Whole 
blood was collected from patients P7 (A), P9 (B), P14 (C) and P16 
(D) throughout four cycles of DAB/IL2 administration (each cycle 
indicated by an arrow). The peripheral blood mononuclear cells 
were isolated from the whole blood by Ficoll gradient centrifuga-
tion and stained with a PE-labeled anti-CD8 monoclonal antibody 
and APC-labeled tetrameric HLA-A2*0201/MART1 (black) or 
gp100 (red) or tyrosinase (green) peptide conjugates. The periph-
eral blood concentration of the indicated melanoma antigen-spe-
cific CD8+ T cells was quantified by multiplying the percentage of 
CD8+/tetramer+ cells within the lymphocyte forward/side scatter 
gate by the absolute lymphocyte concentration determined using 
an automated hematology analyzer. Data are represented as aver-
ages ± standard error of the mean (n = 10 patients). Patient P14 
did not develop detectable tyrosinase- or gp100-specific CD8+ T 
cells but the green line (tyrosinase) is concealing the red line 
(gp100) (C).
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tases (Table 1). However, we observed the regression of
melanoma metastases in only 2/4 HLA-A2*0201+ patients
who developed melanoma antigen-specific CD8+ T cells
(Table 1). We can only speculate that the two patients
who developed melanoma antigen-specific CD8+ T cells
but did not experience tumor regressions may have
melanomas that express low class I MHC or effector CD8+
T cells that are compromised by low affinity T cell recep-
tors and/or the tumor microenvironment. Importantly,
the peptide/MHC tetramers used in this study can only
detect a miniscule fraction of the possible CD8+ T cells
that have specificity for MART1, gp100, tyrosinase or
other melanoma antigens.
Intriguingly, patients P3 and P14 experienced the regres-
sion of multiple metastastic melanomas simultaneously
with the persistence and even growth of other metastatic
melanomas (i.e. a mixed response). The residual peri-aor-
tic mass in patient P14 was confirmed to express the
melanoma antigen, MART1, and this patient developed
peripheral blood MART1-specific CD8+ T cells within 21
days of transient T cell depletion. Despite immunohisto-
chemical evidence that CD8+ T cells appeared to surround
the MART1+  melanoma cells, this residual metastatic
melanoma was not cleared. Interestingly, the melanoma
cells did not express the class I MHC proteins HLA-A, B or
C which may partly explain the lack of regression of this
particular metastasis. We suspect that differences in
melanoma antigen expression and/or additional tumor
immunoevasion tactics also may explain such differential
anti-tumor effects within a single host and future studies
will be directed at further examination of the phenotypes
of melanoma cells and infiltrating immune cells in grow-
ing and regressing melanomas within a single host.
DAB/IL2 administration transiently decreased
CD4+CD25-, CD4+CD25+, CD4+CD25HIFoxp3-,
CD4+CD25HIFoxp3+, CD8+ T cells and, in certain patients,
melanoma antigen-specific CD8+ T cells. These data sug-
gest that DAB/IL2 is not selectively cytotoxic to T regula-
tory cells which may be due, in part, to the high IL-2
receptor expression of activated effector T cells. We found
that all examined T cell subsets repopulated the peripheral
blood and presume that this repopulation is due either to
a proliferative expansion or re-trafficking of T cells from
lymph nodes. Interestingly, CD4+ or CD8+ T cell depletion
in mice has been found to cause a proliferative expansion
of the residual T cells that restores the original T cell pool
size [20]. This peripheral expansion has been termed
homeostatic proliferation and can prevent the induction
of tolerance to transplanted organs and cause anti-tumor
responses against melanomas and colon cancer in mice
[20-22]. Although the mechanisms for these effects are
not well established, homeostatic proliferation of CD4+
and CD8+ T cells is, in part, driven by MHC/peptide recog-
nition. We postulate that transient T cell depletion in can-
cer patients may cause a rebound expansion of T cells with
a shifted TCR repertoire that includes increased
melanoma antigen-specific CD8+ T cells. On-going studies
that examine the relative effects of Treg depletion and
transient total T cell depletion on melanomas in mice and
the consequences of adding back Treg cells or total lym-
phocytes on these effects should improve our understand-
ing of the precise mechanisms for the observed tumor
regressions in melanoma patients.
The effect of DAB/IL2 on both peripheral blood Treg cell
concentration and tumor burden has been previously
examined in 4 patients with metastatic breast, lung or
Table 1: Adverse Events and Clinical Outcomes of DAB/IL2 Administration to Melanoma Patients
ID Age M/F Stage Cycles Adverse Events (grade) Outcome(s) HLA-A2* 0201 CD8+ T Cells
P1 50 F IV 2 Erythema (1) Progressive disease - Not applicable
P2 78 M IV 3 Weakness (1) Progressive Disease - Not applicable
P3 58 M IV 4 None Mesenteric & Hepatic Regressions 
(PR)
- Not applicable
P4 66 F IV 1 None Progressive Disease - Not applicable
P5 72 M IV 2 Pain at tumor site (1) R. Hilar and Colon Regressions (PR) - Not applicable
P6 63 M IV 2 None Progressive Disease - Not applicable
P7 67 M IV 4 None Progressive Disease + MART1+Tyr+
P8 58 F IV 4 None IM & SC Regressions (PR) - Not applicable
P9 46 M IV 4 None Inguinal Regression + MART1+g100+ Tyr+
P10 35 F IV 3 None Progressive Disease + Negative
P11 54 M IV 2 None Progressive Disease + Negative
P12 79 M IV 2 Dermatitis (2) Stable Disease - Not applicable
P13 72 M IV 1 Dehydration (2) Progressive Disease - Not applicable
P14 61 M IV 4 Vitiligo (1) Pulmonary, Hepatic, LN & SC 
Regressions (PR)
+ MART1+
P15 46 F IV 4 None Progressive Disease + Negative
P16 68 F IV 4 Arthritis (2) Dermatitis (1) Progressive Disease + MART1+g100+ Tyr+Journal of Translational Medicine 2008, 6:12 http://www.translational-medicine.com/content/6/1/12
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Regression of hepatic, mesenteric and hilar melanoma metastases after DAB/IL2 administration Figure 7
Regression of hepatic, mesenteric and hilar melanoma metastases after DAB/IL2 administration. A. Patient P3 
was scanned by combination PET/CT imaging 2 weeks prior to DAB/IL2 administration (pre-DAB/IL2) and after completing 
four 3-week cycles of DAB/IL2 (post-DAB/IL2). The brain, heart and bladder have normal accumulations of the PET tracer 18F-
fluorodeoxyglucose but several areas of increased metabolism consistent with melanoma metastases resolved after DAB/IL2 
administration. B. CT imaging of patient P5 revealed a large right hilar mass and a mesenteric mass that both decreased in size 
after DAB/IL2 administration.
P3: Pre-DAB/IL2 Post-DAB/IL2
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Regression of subcutaneous, intramuscular and lymphatic metastases after DAB/IL2 administration Figure 8
Regression of subcutaneous, intramuscular and lymphatic metastases after DAB/IL2 administration. A. The 
right lower extremity of patient P8 was scanned by CT imaging 3 weeks prior to DAB/IL2 administration (pre-DAB/IL2) and 
after completing four 3-week cycles of DAB/IL2 (post-DAB/IL2). The white numbers in the lower left corner of each image 
indicate the distance (mm) above the superior aspect of the patella in order to provide matched images for comparison. B. CT 
imaging of patient P9 revealed a rapidly growing right inguinal mass that decreased in size 3 months after DAB/IL2 administra-
tion. A follow-up scan, 6 months after DAB/IL2 administration, revealed no further growth.
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Stabilization of two right hilar masses in a 79-year old male after DAB/IL2 administration Figure 9
Stabilization of two right hilar masses in a 79-year old male after DAB/IL2 administration. PET imaging of patient 
P12 was conducted 1 month prior and 3 months after 2 cycles of DAB/IL2. Two discrete areas of hypermetabolism in the right 
hilum remained stable during this three month period.
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Post-DAB/IL2 (+3mo)
P12:Journal of Translational Medicine 2008, 6:12 http://www.translational-medicine.com/content/6/1/12
Page 15 of 18
(page number not for citation purposes)
Near complete response of widespread visceralmelanoma metastases after 4 cycles of DAB/IL2 Figure 10
Near complete response of widespread visceralmelanoma metastases after 4 cycles of DAB/IL2. A. Anterior/
posterior views, PET. B. Lateral views, PET. C. CT imaging, liver. D. CT imaging, lungs. Combined PET/CT imaging of patient 
P14 revealed rapid progression of multiple melanoma metastases in the liver, both lungs, lymph nodes and the subcutaneous 
compartment (compare -6 months to -1 week). After 4 cycles of DAB/IL2, the liver metastases completely resolved and the 
lung metastases markedly regressed (compare -1 week to +3 months). Three months after completion of DAB/IL2, the resid-
ual lung metastases had completely resolved but a single enlarged peri-aortic lymph node persisted (red arrow). The increased 
18F-fluorodeoxyglucose uptake in the brain, bladder and both kidneys are due to normal metabolism and are not reflective of 
metastases.
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CD8+ T cell infiltration of residual HLA-A, B and C negative melanoma and evidence for vitiligo after DAB/IL2 administration Figure 11
CD8+ T cell infiltration of residual HLA-A, B and C negative melanoma and evidence for vitiligo after DAB/IL2 
administration. The residual peri-aortic mass in patient P14 was resected, formalin fixed and embedded in paraffin. A. Hema-
toxylin/eosin (H&E) staining of the mass revealed a mononuclear infiltrate that was confirmed to include CD8+ T cells by dou-
ble immunohistochemistry using an anti-CD8 antibody (brown) and an anti-MART1 antibody (red). The counter stain used in 
the immunohistochemistry was hematoxylin and the control consisted of no primary antibody. B. HLA-A, B or C expression 
by cells in the pancreas (top; positive control), an unrelated melanoma metastasis (middle; positive control) and the residual 
peri-aortic melanoma metastasis resected from patient P14 as determined using a monoclonal antibody specific for a non-poly-
morphic portion of these HLA molecules. C. Photographs of patient P14's hair before and after DAB/IL2 administration 
revealed the complete loss of pigmentation.
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ovarian cancer (single infusion; 9 μg/kg or 12 μg/kg) [23].
Prior to infusion, the mean Treg cells/mm3 was found to
be 126 (26.8% of total CD4+ Tcells) and, after DAB/IL2
infusion, the mean Treg cells/mm3 was reduced to 78
(19.0% of total CD4+ Tcells) [23]. A patient with Stage
IIIC, relapsed ovarian cancer received the highest dose of
DAB/IL2 (12 μg/kg) and experienced a marked reduction
in the ovarian cancer marker, CA-125, four weeks after a
single infusion (from 121 U/ml to 38 U/ml) [23]. This
patient was then administered 6 additional doses of DAB/
IL2 weekly (12 μg/kg) and, two months after the final
dose, a PET/CT fusion scan revealed a dramatic reduction
in metastatic burden. In a second study, twelve stage IV
melanoma patients were administered DAB/IL2 at a lower
dose (9 μg/kg) and a higher dose (18 μg/kg) daily × 5 days
every three weeks [24]. The investigators reported that
none of the patients experienced an objective clinical
response and that the expression of the Treg-specific tran-
scription factor Foxp3 and the suppressive ability of
CD4+CD25HI cells did not decrease significantly. The dis-
parity in clinical results between this study and the current
study of melanoma patients may be due to differences in:
(i) the dosing (9 or 18 versus 12 μg/kg); (ii) the duration
of treatment in each cycle (5 daily versus 4 daily doses per
cycle); (iii) the low sample size in both studies; (iv) the
extent of disease in the examined human subjects; (v) the
methods used to measure T regulatory cells (real-time
PCR for Foxp3 versus three color flow cytometry for
CD4+CD25HIFoxp3+ cells); and (vi) the extent of prior
immunotherapeutic treatments that had been adminis-
tered to the patients in each study (e.g. IL-2). Importantly,
in a recent study, DAB/IL2 was found to significantly
reduce the peripheral blood Treg cells in metastatic renal
cell carcinoma patients and to abrogate Treg-mediated
immunosuppressive activity in vivo [25]. This study also
demonstrated that DAB/IL2-mediated depletion of Tregs
followed by vaccination with RNA-transfected DCs
increased the activation of tumor-specific T cell responses
compared to vaccination alone [25].
Conclusion
In conclusion, we have demonstrated that T cell depletion
with DAB/IL2 in melanoma patients is followed by a T cell
repopulation of the peripheral blood, the de novo appear-
ance of CD8+ T cells specific for melanocyte differentia-
tion antigens and regression of melanoma metastases.
This single site, investigator-initiated phase II clinical trial
has been expanded to provide further evidence for the effi-
cacy of DAB/IL2 against melanoma. Future clinical studies
that are conceptually appealing include an examination of
the efficacy of DAB/IL2 in several cancer types and the
potential utility of combination therapy with vaccines or
other immune enhancing agents such as interferon-α.
Last, we anticipate that the limited or pulsed administra-
tion of alternative T cell depleting agents may prove useful
for the activation of cognate immunity against neoplastic
cells in cancer patients.
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